MATERIAL and METHODS: A total of 75 patients retrospectively analysed. The complete blood count of the patients was analysed before surgery. In our study, cut-off values for PLR 150 (platelet-lymphocyte ratio) and NLR 4 (neutrophil-to-lymphocyte ratio) were found to be significant by creating the ROC curve. Overall survival (OS) was calculated from surgery to death or the last contact. Progression-free survival (PFS) was calculated from surgery to progression. The last follow-up was November 2018.

RESULTS: The median OS was significantly shorter in PLR>150 patients (p=0.005; 10 vs 17 months). And the median OS was significantly shorter in NLR>4 patients too (p=0.010; 11 vs 17 months). In multivariate analysis, Karnofsky performance score <70 (HR:2.96, 95% CI:1.68-5.21; p<0.001), type of surgical resection (HR:2.32, 95% CI:1.35-3.98; p=0.002) were statistically significant for PFS. In multivariate analysis, KPS<70 (HR:2.72, 95% CI:1.30-5.67; p<0.007), type of surgical resection (HR:2.09, 95% CI:1.10- 3.95; p=0.023), NLR>4 (HR:2.14, 95% CI:1.11-4.14; p=0.023) were statistically significant for OS were found to be independent prognostic factor.

CONCLUSION: The presence of 704, 70 Keywords : Glioblastoma multiforme, Pretreatment neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, Survival